Market Research Blog – Page 9175 – New Product Development

Actinic Keratosis Treatment Market is expected to reach US$ 8.0 Bn by 2028

[275 Pages Report] The global Actinic Keratosis Treatment Market was valued at US$ 5.0 Bn in 2021 and is expected to reach US$ 8.0 Bn by 2028, finds Future Market Insights (FMI) in a recent market survey.

Global demand for actinic keratosis treatment, majorly driven by that in the U.S. and European countries, continues to grow at a strong rate. Poised for revenues of over US$ 4 Bn by the end of 2019, the global actinic keratosis treatment market will exhibit an impressive CAGR of 7% during the forecast period (2019 – 2029).

The understanding about the nature of actinic keratosis and the potential risk of this condition progressing to squamous cell carcinoma (SCC) is improving, among patients as well as healthcare providers. Especially among the elderly, actinic keratosis remains one of the most commonly diagnosed dermatological condition that creates a continued need for efficacious treatments.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3233

Who Is Winning?

The actinic keratosis treatment market report tracks the key market players, which includes GlaxoSmithKline Plc. Nestle SA, Novartis AG, Sun Pharmaceutical Ltd., Leo Pharma Inc. etc. Leading manufacturers in the actinic keratosis treatment market are focusing on acquisitions to enhance their product portfolio. For instance, in November 2015, Leo Pharma A/S completed the acquisition of dermatology business of Astellas Pharma. With this acquisition, the company expanded its dermatology product portfolio segment. Companies are also focusing on segment leadership. In February 2016, Cipher Pharmaceuticals Inc. launched Actikerall for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis to mark their leadership in topical product segment.

Combination therapies such as topical fluorouracil cryotherapy, PDT and imiquimod therapy, chemical peels, and 5-FU are generally the most prescribed therapies for actinic keratosis. Convenient administration, lower potential for irritation, and systemic absorption continue to underpin their high adoption rate. Development of drugs with increased efficacy and decreased side effects that can be used as combination therapy for actinic keratosis treatment is currently the focal point of global market leaders. Biofrontera AG commercially launched its product Ameluz (2016), used in combination with PDT for actinic keratosis treatment.

Development of minimally invasive drug-device combination therapies and fast track regulatory approval for pipeline drugs will be offering a completely new set of treatment options for actinic keratosis in the near future.

Key Takeaways – Actinic Keratosis Treatment Market Study

Growing use of topical products as the first-line preference for actinic keratosis treatment is offering huge opportunities to market players to develop and launch new topical products for actinic keratosis treatment.
Increasing collaboration activities by key market players of the actinic keratosis treatment market with other companies to broaden their products portfolio is anticipated to propel the actinic keratosis treatment market growth.
- For instance, in March 2017, Galderma SA (Nestle Skin Health Company) collaborated with Colorescience, to enhance its product portfolio for aesthetic treatment.
Increasing product approvals of actinic keratosis treatment by regulatory bodies is expected to fuel the actinic keratosis treatment market growth.
- For instance, in March 2018, combination of Ameluz and daylight photodynamic therapy (PDT) by Biofrontera AG got approval from the European Union.
The U.S. and Australia marking rise in incidence and prevalence of actinic keratosis will remain highly prominent markets for actinic keratosis treatment providers.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3233

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on actinic keratosis treatment market in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of treatment category (topical treatment, procedural modality, photodynamic therapy and others), disease type (clinical AK and subclinical AK)and end-user (hospitals, laser therapy centers, private dermatology clinics, spas and rejuvenation centers, cancer treatment centers, homecare) in seven key regions.
Key Players :

Sun Pharmaceutical Industries Ltd.
Biofrontera
Nestle SA
Bausch Health Companies Inc.
Novartis AG
GlaxoSmithKline plc.
Almirall, LLC
LEO Pharma Inc.
Cipher Pharmaceuticals Inc.
Pierre Fabre Pharmaceuticals, Inc.

Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-3233

Actinic Keratosis Treatment Market By Category

By Treatment Type:

Topical Treatment
- 5-fluorouracil Cream
- Diclofenac Gel
- Imiquimod Cream
- Ingenol mebutate Gel
Procedural Modality
- Chemical Peels
- Cryotherapy
Photodynamic Therapy
Others

By Disease Type:

Clinical AK
Subclinical AK

By End User:

Hospitals
Private Dermatology Clinics
Laser Therapy Centers
Cancer Treatment Centers
Spas and Rejuvenation Centers
Homecare

More Trending Reports by Future Market Research :

Leukemia Therapeutics Treatment Market : During the forecast period, the leukemia therapeutics treatment market is expected to record a CAGR of 7.1 per cent to reach a valuation of US$ 17 Bn by 2024, from a valuation of US$ 13 Bn in 2020.

Non-invasive Surgical Wound Closure Market : The global non-invasive surgical wound closure market is estimated to be valued at US$ 2,192.3 billion in 2022. This market is expected to grow at a CAGR of 4.1% over the forecast period (2022-2032) to reach a market size of US$ 3,404.6 billion by 2032.

Mobile Cardiac Telemetry Systems Market : The global mobile cardiac telemetry systems market enjoys a valuation of US$ 825.3 Mn in 2021, and it is further projected to expand at a CAGR of 12.5% over the forecast years.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Brain Monitoring Systems Market is anticipated to progress at a CAGR of 5.9% to reach a valuation of US$ 6.56 Bn by the end of 2028

The brain monitoring systems market is projected to expand at a healthy pace with global sales exceeding US$ 3.5 Bn by end of 2019, as per the latest research study by FMI. A range of broad factors, including the government funding for development of advanced medical devices, and favorable healthcare reimbursements are key sales influencers of brain monitoring devices.

The FMI report finds that rising prevalence of brain aneurysm and chronic brain injuries have necessitated adoption of brain monitoring systems expediting early and effective treatment. According to the Brain Aneurysm Foundation, nearly 6 million individuals in the U.S. suffer from unruptured brain aneurysm. In the wake of such alarming statistics, the adoption of brain monitoring systems is surging at an impressive rate for revolutionizing patient care.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1259

As per the study, demand for brain monitoring systems significantly took off in parallel with convergence of technology and healthcare, which translated into a massive influx of advanced medical devices with high functionality.

“Rising inclination toward non-invasive procedures is inducing a shift toward devices facilitating seamless observation and identification of neurons without involvement of invasive neurosurgery, such as brain monitoring systems,” says FMI report

The study opines EEG machines to gain significant momentum as widely-preferred brain monitoring systems, with revenues estimated to surpass US$ 1.5 Bn in 2019. Focus on delivering effective treatment via early detection of abnormalities have led the adoption of EEG machines, as these enable beneficial interventions with minimum chances of neurological complications. Simple platforms, effective report generator, and streamlined assessment tools are key attributes of EEGF machines that have driven their preference among patients and physicians alike.

Brain monitoring systems continue to witness significant demand from Hospitals (ICUS and adult care), with revenue expected to cross US$ 1 Bn in 2019. In response to high demand from hospitals, EEG machine manufacturers are implementing novel product development strategies, to realize enhanced profit margins.

Convergence of IOT with Brain Monitoring Space – A Key Trend Fostering Functionality with Better Connectivity

Penetration of IoT in the medical devices and systems landscape shows no signs of abating, evolving as a promising breakthrough that could result in connected ecosystems for brain monitoring devices with enhanced functionalities. IoT continues to play a major role in redefining interactions among various components of a brain monitoring system, thereby resulting in reduced costs, improved outcomes, and enhanced patient experiences. This trend is further complemented by on-going research efforts by prominent universities. For instance, a cohort of researchers at the Wits University of South Africa developed a way to connect human brains with internet on a real-time basis.

The transition toward miniaturized and portable models is gaining swift momentum in the brain monitoring systems landscape, as patients actively seek for advanced devices with new modalities, such as Functional Near-Infrared Spectroscopy (fNIRS), which enable real-time monitoring. The research study by FMI finds that future adoption of such upgraded versions will remain significant among physicians, as these facilitate seamless capture, storage, and processing of neurological information.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1259

Major players are making headway with strategic partnerships, acquisitions, and mergers to attain competitive advantages and access a wide-range range of resources and expertise. For instance, Philips acquired Electrical Geodesics, Inc. in 2017 with an objective to establish a new integrated neurological imaging, mapping and therapy guidance portfolio. Partnerships as such are foreseen to help in organic growth of the market players via collaborative innovations.

The FMI report covers assessment and forecast of the brain monitoring systems market for the period of 2018 to 2028. According to the report, the brain monitoring systems market is expected to grow at a CAGR of over 6% through 2028.

Competitive Landscape

This section of the report features profiles of key players operating in the brain monitoring systems market based on their market shares, differential strategies, brain monitoring systems product offerings, marketing approach and company dashboard.

Examples of some of the key players featured in this report include

Nihon Kohden Corporation., Electrical Geodesics, Inc. (Koninklijke Philips N.V.), Siemens Healthcare GmbH, Hitachi Ltd Natus Medical Incorporated, Medtronic plc. Compumedics Ltd, Neurosoft, EB Neuro S.p.A, and Ricoh Company Ltd among others.

The key manufacturers of brain monitoring systems are focusing on marketing strategies to increase both their product portfolio as well as geographical presence. The company’s manufacturing brain monitoring systems are focused on pricing strategies in order to lead in the market for brain monitoring systems.

Some other key market strategies followed by brain monitoring systems manufacturers include distribution & collaboration agreements to increase product reach, partnering with local as well as global retailers, and long-term partnerships with ambulatory surgical centers, clinics, hospitals and other distributor channels such as neonatal and pediatrics ICUs

Key Segment

Based on product type

fNIRS

EEG Systems

MEG Systems

MRI Systems

other brain monitoring systems

Based on modality

Portable/Handheld Systems

Standalone Systems

Based on end-users

hospitals

ambulatory surgical centers

clinics

pediatric & neonatal intensive care units

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1259

Based on region

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

China

Japan

MEA

About FMI:

3D Cell Culture Market stands at a net worth of US$ 1.15 Billion in 2022 | Get Insights FMI

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

A steady rise in global research and development expenditure
Efforts to leverage the potential of 3D cell culture to replace animal model testing
Increasing demand for biosimilar products
Extensive application of stem cell research and a growing emphasis on regenerative medicine

3D Cell Culture Market

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material – natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

“While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years,” says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

Thermo Fisher Scientific Inc.,
Merck KGaA,
Becton,
Dickinson and Company, and Lonza,
Corning Incorporated,
Synthecon, Inc.

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key Segment Based on product type

scaffold-free 3D cell culture
scaffold-based 3D cell culture

Based on application

drug discovery
tissue regeneration & regenerative medicines
cancer research
stem cell technology
others

Based on end user

biotechnology and pharmaceuticals industries
hospital laboratories
academic research and institutes
contract research organizations

About FMI:

Loop-mediated Isothermal Amplification (LAMP) Market is projected to reach US$ 120.4 Million by 2028 | FMI

Global demand for loop-mediated isothermal amplification technology reached around US$ 85 million in 2018, as indicated by a new research study of Future Market Insights (FMI). Estimated to observe stable growth in revenue over the coming years, loop-mediated isothermal amplification market will witness dominance of DNA polymerase, among the various product types.

Dominance of DNA Polymerase Adoption to Prevail, LAMP Instruments to Emerge Lucrative

DNA polymerase will continue to find highest applicability in both research and diagnostics. According to FMI’s report, DNA polymerase will be the key revenue generating product in loop-mediated isothermal amplification market over the period of projection. However, the report also highlights that instruments such as turbidimeters and fluorescence measuring systems will prominent traction in loop-mediated isothermal amplification market through 2028.

Amongst various loop-mediated isothermal amplification technologies, micro-fluidic technology majorly, have been successfully used in the diagnosis of several diseases including malaria and tuberculosis. Loop-mediated isothermal amplification using DNA polymerase has seen a rapid rise in the past several years due to the high adoption of loop-mediated isothermal amplification in testing.

The application of these Loop-mediated isothermal amplification in assessing and directing diagnosis in certain types of disease, such as acute malaria, has provided a new dimension to the gradually growing field of minimal residual disease management.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5532

High Penetration of Cutting-edge Technology Molecular Diagnostics of Fatal Diseases to Push LAMP Market Growth

The simplicity sensibility and specificity of loop-mediated isothermal amplification puts it in a very good position for future development in life threatening disease diagnosis. It is anticipated that the loop-mediated isothermal amplification market will grow significantly during the forecast period, owing mainly due to demand for advanced molecular diagnostics to accurately diagnose life-threatening diseases.

In recent years, the detection and identification of nucleic acids using point-of-care total nucleic acid analysis systems and procedures are in rise including loop-mediated isothermal amplification in various clinical and industrial settings. Besides loop-mediated isothermal amplification has also challenged PCR based amplification as it could achieve enhanced nucleic acid amplification by increasing surface area to volume ratio with reduced testing cost.

Macroeconomic indicators such as government funding for advancement and increased research on disease epigenetics; establishment of network of distribution and marketing agreements to ensure availability of products to different loop-mediated isothermal amplification end users globally; liberalization of import and export trade on point of care diagnostic devices and chemical reagents are also anticipated to propel the growth of the loop-mediated isothermal amplification market.

Key Challenges Facing Development of Loop-mediated Isothermal Amplification Market

On the grey side, loop-mediated isothermal amplification has several intrinsic disadvantages such as its amplification method is devoid of an internal PCR inhibition control (IC). It is essential to perform all the reactions in duplicate, one being or the target and the other one for the IC in loop-mediated isothermal amplification assay.

Moreover, most standard DNA polymerases are unable to exhibit activity in samples derived from crude lysate due to the presence of polymerase inhibitors. This adds complexity to the loop-mediated isothermal amplification processing due to additional steps involved in purifying DNA to be used for amplification, which could also result in loss of starting material.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-5532

Loop-Mediated Isothermal Amplification Market: Additional Questions Answered

What is the revenue potential of the Loop-Mediated Isothermal Amplification Markets across North America and Europe?
Who are the key competitors and what are their portfolios in the Loop-Mediated Isothermal Amplification Market?
What are the major challenges influencing the growth of the Loop-Mediated Isothermal Amplification Market?
How is intervention from regulatory authorities shaping the growth of the Loop-Mediated Isothermal Amplification Market?

Regions with High Disease Prevalence to Reflect High Growth Potential for LAMP Market

Due to increase in prevalence of malaria and other pandemic diseases, regions such as East and South Asia are anticipated to be the fastest growing regional loop-mediated isothermal amplification markets and are poised to offer tremendous opportunities to key players. The increase in disease prevalence will increase the demand for the use of loop-mediated isothermal amplification for point-of-care diagnosis. Besides, distribution & collaboration agreements by leading players of loop-mediated isothermal amplification products with the established local distributors in the regions will fuel the market growth of both the regions.

The loop-mediated isothermal amplification market report tracks some of the key companies operating in the global loop-mediated isothermal amplification market such as :

Eiken Chemcial Co.Ltd
New England Biolabs
Jena Bioscience GmbH
NIPPON GENE CO.
LTD
HUMAN
Optigene
HiberGene Diagnostics
Meridian Bioscience Inc.
Mast Group Ltd.

Key Segment

Based on product type

instruments
- incubation systemsTurbidimeters
- Agarose gel electrophoresis
- fluorescence measuring systems
kits & reagents
- DNA polymerase
- Primer Mix
- DNA Polymerase &Primer mix
- dyes
- other reagents

Based on Technology

microfluidic technology
advanced infrared optical technology
modern microsystem technology

Based on Application

diagnostic
research purpose

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-5532

Based on End User

hospital & laboratories
research & academic institutes
others

About FMI:

Hematology Diagnostics Market Is estimated To Reach US$ 1.2 Billion by the End of 2031 | FMI

Standing at a valuation of US$ 725 Mn in 2022, the global hematology diagnostics market is projected to reach US$ 1.2 Bn by the end of 2031. Demand for hematology diagnostics is anticipated to increase at a CAGR of 5.8% from 2022 to 2031.

The Hematology Diagnostics Market has witnessed the advent of a wide range of hematology testing solutions that combine the attributes of strainer, slider maker, and cell counter. Integrated solutions have been gaining ground in the hematology diagnostics market, as growing work load has prompted pathologists to adopt methods with precision and accuracy for improved results.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-9046

According to a recent study of Future Market Insights (FMI), the hematology diagnostics market recorded a valuation of approximately US$ 3,500 Mn in 2017. Growing popularity of modern day analyzers that offer five to seven parts white cell differential analysis, along with additional information on cell population data (CPD), large unstained cell population, and granularity index, will continue to drive growth of the hematology diagnostics market.

The study opines that the hematology diagnostics market will continue to remain a consolidated landscape, with few established players collectively accounting for a larger share of the market. Robust portfolio, and stronger distribution footprint of these leading players, including F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Abbott Laboratories, and Sysmex Corporation, will continue to uphold their lead in the hematology diagnostics market in the upcoming years.

Key players in the hematology diagnostics market are focusing on strategic partnerships with vendors having innovative technologies, to gain a greater share with more diverse portfolios. Other leading players profiled in the report on the hematology diagnostics market include HORIBA, Ltd., HemoCue AB, Mindray Medical International Limited, Danaher (Beckman Coulter, Inc.), Bio-Rad Laboratories, Inc., and Siemens Healthineers.

For any Queries Related with the Report, Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-9046

Emphasis on Effective Hematology Diagnostics to Surge in Line with Prevalence of Blood Cancer

There has been a marked rise in the prevalence of blood disorders, and the pervasiveness of these ailments will continue to surge in the foreseeable future, according to the report. This has further driven the essentiality of hematology diagnostics with greater efficacy, thereby complementing new product developments and technological advancements in the hematology diagnostics market worldwide.

Recent studies from associated regulatory authorities estimated that, in the US alone, number of individuals affected with blood-related disorders reached nearly 173,000 in 2017. This has further led the healthcare institutes and governments to take up initiatives for increasing awareness of these disorders and the availability of related management & treatment procedures, which in turn has led the demand and adoption of hematology diagnostics in the recent past.

Point-of-care testing has also witnessed a notable rise in demand, with technological advancements leading to results with higher accuracy and convenience. Easy availability of myriad test methods for hematology diagnostics has also been a key factor driving growth of the market. The study estimates that the hematology diagnostics market

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-9046

Gains from Hematology Diagnostics Market in Developed Markets to Remain Higher

The study anticipated Europe and North America to remain the most lucrative markets for the hematology diagnostics market. Relatively greater prevalence of blood-related disorders, higher awareness about the existing screening techniques for blood disorders, and rising expenditure on health & wellness by consumers, allude greater gains from the hematology diagnostics market in Europe and North America.

Sensing varied requirements of the healthcare settings and the distinctions in the blood ailments, key players in the hematology diagnostics market have introduced a wide range of hematology instruments, According to the study, hematology analyzers currently accounts for the largest share in the hematology diagnostics market.

About FMI:

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market is projected to attain a valuation of US$ 39.5 Billion by 2028

The approximately US$ 25 Bn market for benign prostatic hyperplasia prostate treatment is likely to expand at 4.6% CAGR during 2018-2028, according to a recent research report of Future Market Insights (FMI). The report has envisaged steady growth prospects for the revenue of global benign prostatic hyperplasia prostate treatment market through 2028.

The World Population Prospects’ data (2017) projected that the number of individuals aged 60 years and above will double by 2050, and triple by 2100. With such a high pace estimated for the growth of population aged 60 years and above, it is more likely that the prevalence of aging related health conditions will also increase at a considerable pace in the years to come. A high prevalence rate of benign prostatic hyperplasia (BPH) in men, the demand for improved and more effective treatment options continues to increase at a high rate.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1664

Alpha-blockers & Drugs for Lower UTIs Remain Pivotal in Benign Prostatic Hyperplasia Prostate Treatment

The drug treatment has been vital in treating benign prostatic hyperplasia conditions and lower UTIs, which has been attributed to widespread availability of drug-based benign prostatic hyperplasia prostate treatment. This factor, in particular, will play an instrumental role in driving the growth of the benign prostatic hyperplasia prostate treatment market during the forecast period. Drugs will remain the first choice of treatment for benign prostatic hyperplasia.

Benign prostatic hyperplasia increases the risk of other disorders as well. The most common disorder caused due to benign prostatic hyperplasia is lower UTI (urinary tract infection) for which, Alpha-blockers constitute the first line of treatment. However, other drugs are also available in the market, which offer relief from the benign prostatic hyperplasia symptoms. Other drugs include alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs.

Key Players:

Pfizer, Inc.,
Valeant Pharmaceuticals Inc.,
Novartis AG,
Bayer AG,
Sanofi S.A.,
GlaxoSmithKline plc.,
Bristol-Myers Squibb and Company,
Teva Pharmaceutical Industries Ltd,
Mylan N.V.,
Merck & Co.,
Cardinal Health Inc., and
Eli Lilly and Company among others.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1664

Additional Questions Answered

Additional questions addressed in this benign prostatic hyperplasia prostate treatment market report are:

What is the revenue potential of the benign prostatic hyperplasia prostate treatment market across North America and Europe?
Who are the key players and what are their product portfolios in the benign prostatic hyperplasia prostate treatment market?
What are the major challenges impacting the growth of the benign prostatic hyperplasia prostate treatment market?
How is the involvement from key regulatory bodies shaping the growth of the benign prostatic hyperplasia prostate treatment market?

Demand for Benign Prostatic Hyperplasia Prostate Treatment Higher in Developed Regions, Patient Pool Expanding Steadily in Developing Markets

Owing to significantly growing prevalence of benign prostatic hyperplasia in North American men, benign prostatic hyperplasia prostate treatment market is expected to witness strong growth within the region, followed by Europe.

Extensive availability of benign prostatic hyperplasia prostate treatments, increasing clinical trials, improving R&D scenario, higher healthcare spending, and favorable government initiatives will continue to assist the growth of the benign prostatic hyperplasia prostate treatment market in developed regions.

On the other side, Asia Pacific’s benign prostatic hyperplasia prostate treatment market is foreseen to witness significant growth, owing to steadily expanding patient pool due in the region.

UroLift System to Revolutionize the Competitive Landscape of Benign Prostatic Hyperplasia Prostate Treatment Market

Teleflex Incorporated’s NeoTract recently launched UroLift® System as a highly effective, least invasive option for benign prostatic hyperplasia prostate treatment. The UroLift® System is permanently implanted via a transurethral outpatient procedure and predominantly relieves prostate obstruction, which is one of the primary symptoms of benign prostatic hyperplasia. The company has also declared insurance coverage for UroLift® System. While the coverage is being provided by Humana, it is most likely to improve awareness about increasing availability and broadening access of minimally invasive treatment methods in urological conditions such as benign prostatic hyperplasia. This in turn will encourage adoption of UroLift® System among patients seeking effective benign prostatic hyperplasia prostate treatment.

A majority of patients with enlarged prostate continue to perceive medication and surgery as the only available treatment alternatives. However, an increasing number of physician recommendations is advocating the use of The UroLift® System as it eliminates side effects associated with other conventional options of benign prostatic hyperplasia prostate treatment.

For more insights on the overall performance of global benign prostatic hyperplasia prostate treatment market through 2028, write to press@futuremarketinsights.com

Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-1664

Key Segment

Based on treatment type

alpha-blockers
alpha reductase inhibitors
phosphodiesterase-5 (PDE-5) Inhibitors
muscarinic receptor antagonist
combination drugs

Based on distribution channel

institutional sales
retail sales
online pharmacies

About FMI:

Oxycodone Market Key Players, Applications, Outlook, SWOT Analysis And Forecasts By 2031

According to a recently updated analysis by Future Market Insights, oxycodone sales will grow at a 4.8% CAGR between 2021 and 2031. The oxycodone market is expected to exceed US$ 4.6 billion in 2021, owing to rising demand for effective pain treatment solutions.

Oxycodone belongs to a group of opioid analgesics that is generally used in pain management. It is used for both long and short term. Rising prevalence of orthopaedic diseases such as osteoporosis, fibromyalgia, rheumatoid arthritis and other types of chronic pain is boosting the demand for oxycodone in the global market.

According to the International Osteoporosis Foundation, osteoporosis is one of the most serious health concerns among women and around 30% of people in U.S and Europe are affected by it each year. Increasing medical ailment and post-operative pain is another factor influencing the demand for oxycodone market globally.

The market growth is expected to accelerate due to increasing research and development activities undertaken to innovate abuse-deterrent formulations. Advance drug formulation such as extended-release medication for pain relief is an example of improve formulation.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7638

The market however could face certain restrains in growth as oxycodone has side effects such as bladder pain, abdominal cramps, vomiting, diarrhoea, and breathing problem. Moreover, overdose of oxycodone can lead to de-addiction. The market can also be impacted due to certain severe adverse psychological problems such as depression.

COVID-19 pandemic has affected healthcare industry as there has been a sharp reduction in demand due to lesser visits to healthcare facilities such as clinics and hospitals. The widespread of virus has affected workforce in hospitals and other staffing issues as well.

Key Takeaways from FMI’s Oxycodone Market Study

Increasing penetration of pain management drugs, coupled with favourable reimbursement policies will drive sales in the U.S.
Within the Middle East and Africa, the demand in GCC countries will rise backed by investment towards expansion of the healthcare sector
The U.K., Italy, and France are likely to account for sizeable share in the Europe market for oxycodone
Long-acting oxycodone sales will rise steadily owing to surging application in pain management
Hospital pharmacies will continue exhibiting high demand for oxycodone, driven by higher footfall of patients

Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-7638

Who is Winning?

The key payers operating in the global oxycodone market are focusing on adopting numerous strategies such as mergers and acquisitions, research and development activities, and joint ventures. The key players operating in the global market are Janssen Pharmaceuticals (A Johnson and Johnson Subsidary), Inc., Purdue Pharma L., Hikma Pharmaceuticals USA, Inc., Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Sanofi-Aventis S.A., and others.

FDA in 2017 approved RoxyBond, a novel formulation of immediate-release oxycodone. This is the first approved immediate release opioid analgesic formulation with labelling that describes its abuse-deterrent properties.
In September 2019, Daiichi Sankyo Company in Japan, launched its generic formulated oxycodone hydrochloride hydrate extended release tablets for cancer pain treatment.

More Insight on the Global Oxycodone Market

In the latest study, Future Market Insights gives a detailed insight on the global oxycodone market, providing historical data for the period from 2016 to 2020 and forecast statistics for the period of 2021 – 2031. To understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (long-acting oxycodone and short-acting oxycodone), application segment (pain management and de-addiction), distribution channel (hospitals pharmacies and retail pharmacies), and region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-7638

Key Segments Covered in Oxycodone Market Study

By Oxycodone Type:

Long-acting oxycodone
Short-acting oxycodone

By Application:

Pain Management
De-addiction

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies

By Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain:

About Future Market Insights (FMI)

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Disposable E-Cigarettes Market Worth US$ 18.32 Billion By 2032 | CAGR 11.2% – By FMI

The global disposable e-cigarettes market size is expected to be valued at US$ 6.34 Billion in 2022. With growing demand for non-tobacco products owing to rising health concerns among others, the overall demand for disposable e-cigarettes is projected to grow at a CAGR of 11.2% between 2022 and 2032, totaling around US$ 18.32 Billion by 2032. Disposable e-cigarettes are assumed to be a safe alternative to rechargeable e-cigarettes, which in turn is expected to fuel the market growth during the forecast period. Additionally, increasing acceptance of different vaping devices among young adults and adolescents is set to fuel the growth of the Disposable E-cigarettes Market.

The key players in the market started offering these products online through various e-commerce websites such as Amazon. According to an article published by Truth Initiative, in June 2021, online retail for e-cigarettes including disposable products was 28%. In addition, the availability of approved disposable e-cigarettes from various health bodies such as the National Medical Products Administration (NMPA), as a better alternative to tobacco smoking, will integrate well with the growth trend.

The rising traction of using disposable e-cigarettes among consumers, especially the millennial population, is expected to accelerate the market in the forthcoming years. Key players are launching new and innovative products to comply with the growing demand for these products among consumers. For instance, in January 2021, Dinner Lady, a U.K.-based vape brand launched a disposable vape pen, available in eight flavors, including Lemon Tart, Banana Ice, Citrus Ice, and Strawberry Ice. The initiative was taken to support consumers in terms of health, and bring them towards more sustainable options from combustible cigarettes.

North America dominated the disposable e-cigarettes market and accounted for the maximum revenue share of 49.8% in 2021. The increasing popularity of flavoured disposable e-cigarettes offered by brands such as Puff Bar, Vuse, and Suorin, is one of the major factors that is expected to drive the growth of the industry in the region.

Request a Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15425

Key Takeaways from the Market Study

Global Disposable E-cigarettes Market was valued at US$ 6.34 Billion by 2022-end
From 2017 to 2021, Disposable E-cigarettes demand expanded at a CAGR of 5.6%
By Flavour, the Non-Tobacco category is expected to constitute the bulk of Disposable E-cigarettes Market during the forecast period.
By Distribution Channel, the Offline segment dominates the Disposable E-cigarettes Market.
From 2022 to 2032, Disposable E-cigarettes sales are expected to flourish at a CAGR of 11.2%.

“Demand for non-tobacco products is expected to augment the growth of the disposable e-cigarettes market in the near future. It has been observed that older people prefer this product as it does not have any negative effect on health,” remarks an FMI analyst.

Competitive Landscape

Players in the global Disposable E-cigarettes Market focus on expanding their global reach through various strategies, such as; partnerships, collaborations, and partnerships. The players are also making a significant investment in R&D to add innovations to their products which would help them in strengthening their position in the global market. Some of the recent developments among the key players are:

In May 2022, Flawless, one of Europe’s largest vaping distributors signed an exclusive agreement with the leading Chinese manufacturer of vape disposables, ELF BAR, to create the Gee600 disposable device, for the U.K.’s vape and FMCG sector.
In April 2022, Vaptex launched a new vape device GORIN MAX 4500 puffs adjustable airflow disposable pod, which extends some features between TAKIN and GORIN for a better combination for all vapers
In August 2019, VPR Brands, a market leader and pioneer in e-cigarettes and vaporizers for nicotine, cannabis, and cannabidiol (CBD), announced the re-launch of its most popular e-cigarettes brand, KRAVE, an exceptional tasting, high-quality alternative to cigarettes.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/broc hure/rep-gb-15425

Know More about What the Disposable E-cigarettes Market Repost Covers

Future Market Insights offers an unbiased analysis of the global Disposable E-cigarettes Market, providing historical data for 2017-2021 and forecast statistics from 2022-2032.

To understand opportunities in the Disposable E-cigarettes Market, the market is segmented on the basis of product, portability, and application across five major regions.

About Consumer Product Division at Future Market Insights

The consumer product team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

Key Segments Covered in the Disposable E-Cigarettes Industry Analysis

Disposable E-Cigarettes Market by Flavour:

Non-Tobacco Flavoured Disposable E-Cigarettes
Tobacco Flavoured Disposable E-Cigarettes

Disposable E-Cigarettes Market by Distribution Channel:

Online Distribution Channel of Disposable E-Cigarettes Market
Offline Distribution Channel of Disposable E-Cigarettes Market

Disposable E-Cigarettes Market by Region:

North America Disposable E-Cigarettes Market
Latin America Disposable E-Cigarettes Market
Europe Disposable E-Cigarettes Market
Asia Pacific Disposable E-Cigarettes Market
Middle East & Africa Disposable E-Cigarettes Market

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15425

Table of Content

Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions/Exclusions

Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Flavor modifications /Innovation

Key Success Factors

4.1. Strategic Developments

4.2. Key regulations

4.3. Flavor USPs /Technology

4.4. List of Manufacturers and Providers

Get detailed TOC @ https://www.futuremarketinsights.com/toc/rep-gb-15425

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com

Allergy Diagnostics Market is expected to grow at an 11.3% CAGR from 2022 to 2032 | FMI

[170 Pages Report] According to ESOMAR-certified Future Market Insights’ (FMI’s) research report, the demand for allergy diagnostics has been increasing significantly due to rising incidence of allergic asthma and food allergies across the globe. As per the study, the global allergy diagnostics market is anticipated to grow at around 11.6% CAGR throughout the forecast period from 2021 to 2031.

According to the report, growing incidence of drug allergies especially from penicillin and morphine has fueled the demand for allergy diagnostics across the globe.

The report also states that increasing air pollution and lack of awareness regarding food and drug allergy in emerging and poor countries are encouraging market players towards developing cost effective allergy diagnostics kits.

According to a report published by the World Health Organization, globally around 262 million people are impacted by asthma out of which 461,000 die from asthma.

Rising demand for effective treatment and addressing causes of asthma will aid the overall expansion of the allergy diagnostics market.

Allergy diagnostics market experienced sluggish growth during the COVID-19 pandemic. This is because the pandemic led to suspension of immunological care and diverted the healthcare professional towards treating COVID patients.

In case of patients with severe asthma or other allergic reaction, virtual care and limited visiting methods were employed to restrict the human contact and stop the virus transmission.

Introduction of cost effective at-home food sensitivity and allergy diagnostic will boost the market growth in upcoming years. Such applications will reduce the burden on hospital and laboratories culminating to reduced allergy diagnostic and medical cost.

In the future, the market is anticipated to grow significantly, as majority of diagnostic laboratories and hospitals are inclining towards automated allergy diagnostics for its high effectiveness. Canada and U.S are likely to yield highly opportunistic prospects, contributing towards the overall expansion of the market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4959

“Surge in food allergies cases along with increasing incidence of asthma in children will catapult the demand of allergy diagnostics during the forecast period,” says the FMI analyst.

Competitive Landscape

Allergy diagnostics market is highly competitive market owing to presence of global market players. Market players are employing multiple marketing techniques to expand their global outreach.

Allergy diagnostics market players are focusing towards employing organic and inorganic strategies to expand their global foothold.

Inorganic strategies include strategic merger and acquisition and forming an alliance with regional distributors to strengthen their supply chain channels.

They are also emphasizing towards faster product approvals, product development and patenting.

Prominent players operating in the allergy diagnostics market are:

Hitachi Chemical Co. Ltd
Thermo Fisher Scientific Inc.
Siemens Healthineers
Danaher Corporation
HOB Biotech Group Co
bioMérieux
Hycor Biomedical Inc.
Stallergenes Greer
R-Biopharm AG
Lincoln Diagnostics Inc.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4959

Key Takeaways from FMI’s Allergy Diagnostics Market Study

The U.S is expected to dominate allergy diagnostics market on the back of rising incidence of skin allergies especially eczema and skin inflammation along with high rate of allergic rhinitis (hay fever) in black American population.
Presence of advance healthcare infrastructure, favorable government and insurance policies, and increased per capita income are key allergy diagnostics market drivers in Canada.
The U.K. will offer lucrative opportunities owing to increasing awareness regarding asthma and other allergic reactions like atopic eczema and hay fever. High prevalence of allergies will fuel the demand of allergy diagnostics in the country.
Increasing per capita income and increasing government and private funding towards spreading asthma awareness will boost the allergy diagnostics market sales in China.
India has low per capita income and presence of sub-par healthcare system. High prevalence of myths and stigmatic beliefs regarding asthma is one of the main factors limiting the market growth.

More Insights on the Global Allergy Diagnostics Market

In its latest report, FMI offers an unbiased analysis of the global allergy diagnostics market, providing historical data for the period of 2017-2022 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (fungal allergy diagnostic and neutral lactase enzymes), by allergen type (inhaled allergens, food allergens, and drug allergens), test type (in-vivo allergy tests and in-vitro allergy tests), and end user (diagnostic laboratories, hospitals, and academic research institutes) across North America, Latin America, Europe, East Asia, South Asia, and Middle East and Africa.

About FMI:

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Americas COVID-19 Testing Market is expected to surpass US$ 7,264.4 Mn by 2031 | FMI

[200 Pages Report] The market is set to expand due to frequent mutations in the virus that may lead to further outbreaks. Leading organizations within the market are set to focus on research and development to offer an early and precise diagnosis of the COVID-19, besides offering effective patient care.

Some of the leading players in the Americas COVID-19 testing market include but are not limited to Sky Medical Supplies & Equipment LLC., Sugentech, Inc., Novacyt Group, Aurora Instruments Ltd., PRIMA Lab SA, SD Biosensor, INC., Gold Standard Diagnostics, Eurofins Technologies, Biomerieux SA, and Danaher.

According to Future Market Insights (FMI), the demand for COVID-19 testing is expected to reach a valuation of US$ 4,507.8 Mn in the Americas by the end of 2021. The pandemic is spreading on a global scale at a very high pace. It can cause various health concerns including cardiovascular diseases, kidney failure, and more.

To overcome the problems related to COVID-19, it is important to diagnose the ailment at an early stage of infection. According to the World Health Organization (WHO), more than 180 million positive cases of COVID-19 were diagnosed till June 2021. The rate of positive cases can be controlled with early diagnosis and treatment.

SARS-CoV-2 antigen rapid test kits are the most common type of test that accounted for value USD 2,903.0 Mn in 2020. It is widely accepted due to convenience, ease and rapid nature in the diagnosis process.

The demand for point of care testing is increasing due to advantages such as lower time requirements, at home services, and cost effectiveness. These factors are going to bolster the demand for point of care testing during the forecast period. For instance, on 28 July 2020, Roche announced the launch of the SARS-CoV-2 Rapid Antibody Test in collaboration with SD Biosensor Inc.

With the launch of vaccines and development of mass vaccination programs by governments, the number of COVID-19 cases is expected to drop by the end of 2021, however, it is expected that testing will continue even as lockdown in many countries will be lifted. Key players are focused on strengthening their mergers and acquisitions with new discoveries of technologies.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13636

Key Takeaways from COVID-19 Testing Services Market Study

SARS-CoV-2 antigen rapid test kits are expected to account for over 67% the Americas COVID-19 testing market share by 2031, owing to higher efficacy in diagnostics.
Hospital pharmacies accounted for more than 32% of the market share in 2021. The soaring influx of patients for treatment and intensive care support has driven growth.
Canada will reflect relatively steady growth with a 4.8% CAGR, driven by the matured, government funded healthcare system.
The U.S. will reflect fast growth at a CAGR around 5.7% through 2021-2031. U.S. holds the lead owing to, high healthcare expenditure, and the presence of leading players.
Brazil is the leading country in Latin America, estimated to account for about 54% of the regional share in 2021, supported by easier access to required technologies.

“The shift in focus from testing to vaccination is expected to hamper market growth in the near future. However, the focus on testing for international travel, frequent testing of medical staff and testing for patients with flu like symptoms are expected to continue aiding market growth,” says the Future Market Insight analyst.

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global COVID-19 testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the COVID-19 testing treatment market on basis of the test type in detail, cover every aspect of the market such as Test type, sample type, distribution channel across North America and Latin America region.

Americas COVID-19 testing Market by CategoryTest Type:

SARS-CoV-2 IgM/IgG Antibody Rapid Test Kits
SARS-CoV-2 Antigen Rapid Test Kits
Multiplex Real-Time RT-PCR Assay Kits

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13636

Sample Type:

Blood
Nasopharyngeal Swabs

Distribution Channel:

Hospital Pharmacies
Diagnostic Laboratories
Retail Pharmacies
Drug Store
Online Sales Channels

Region:

North America
Latin America

About FMI:

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs